Skip to content

Impact of Sleep Extension in Adolescents

Impact of Sleep Extension on Insulin Sensitivity and Dietary Intake in Adolescents

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03500458
Acronym
SUNRISE
Enrollment
75
Registered
2018-04-18
Start date
2018-10-15
Completion date
2025-05-31
Last updated
2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dietary Habits, Insulin Sensitivity, Sleep

Brief summary

Many teenagers do not get enough sleep. Obesity and diabetes are increasing in teenagers as well. This study plans to learn more about sleep and insulin resistance (insulin not working) in teenagers, and how these things may be related depending on sleep. This is important to know so that the investigators understand how sleep may play a role in health conditions like extra weight gain (increased food intake and less physical activity) and diabetes. To answer this question, the investigators plan to enroll teenagers who get \<7 hours of sleep on school nights and measure changes in insulin sensitivity and dietary intake after a week of typical sleep (sleeping on their normal school schedule) and a week of longer sleep (spending 1+ hour longer in bed each night).

Interventions

BEHAVIORALSleep Extension

Participants will be asked to increase time in bed at least 1 hour more than baseline

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
14 Years to 19 Years
Healthy volunteers
Yes

Inclusion criteria

1. High school students between the age of 14-19 years 2. have typically insufficient sleep, defined by ≤ 7 hours per night on school days 3. BMI 5th-84th percentile for age and sex 4. habitually sedentary (\< 3 hours of regular physical activity per week) 5. Tanner stage 4 or 5, based on breast development for girls and testicular size for boys.

Exclusion criteria

1. Any medications that affect IR or sleep (e.g., metformin, stimulants, atypical antipsychotics, current use of oral steroids) 2. regular use of melatonin or other sleep aids 3. a prior diagnosis of a sleep disorder (e.g. insomnia, delayed sleep phase syndrome, obstructive sleep apnea) 4. Type 2 diabetes or prediabetes 5. IQ\<70 or severe mental illness that may impact sleep or ability to consent/assent (e.g., schizophrenia, psychotic episodes) 6. teens not enrolled in a traditional high school academic program (e.g., home school students) 7. schedules that would preclude participants from adhering to the sleep manipulation (e.g. night shift employment) 8. travel across more than two time zones in the 2 weeks prior to the study.

Design outcomes

Primary

MeasureTime frameDescription
Change in Insulin Sensitivity2 weeks after Baseline and 7 weeks after BaselineInsulin sensitivity assessed two times with an insulin-modified intravenous glucose tolerance test.
Change in Sleep Duration & TimingAt Baseline, 1 week after Baseline, and 6 weeks after BaselineAssessed three times with a wrist-worn Actigraphy
Change in Physical activityAt Baseline, 1 week after Baseline and 6 weeks after BaselineAssessed three times with a triaxial thigh-worn ActivPal
Change in Dietary Intake1 week after Baseline and 6 weeks after BaselineParticipants will be asked to complete diet diaries two times for 3 days during each sleep condition (prior to each overnight assessment), listing all food and drink consumed, estimated portion size, and timing of consumption.

Secondary

MeasureTime frameDescription
Change in glycemic variability2 weeks after Baseline and 7 weeks after BaselineAssessed two times with a continuous glucose monitor
MTNR1B rs10830963 SNP2 weeks after BaselineGenotyping will be conducted on saliva samples

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026